Tag Archives: DIA

Open Payments: A New Dawn for Transparency

The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realised. Michael Christel reports.
Posted in compliance, Events, FDA, Meetings, Regulatory | Also tagged , , , , | Leave a comment

Key Clinical Trial Themes from DIA 2014

The Drug Information Association (DIA), one of the largest non-profit organizations supporting clinical research and drug development, held its 2014 annual meeting in San Diego last week. Applied Clinical Trials’ Moe Alsumidaie looks at three of the key themes from this year’s meeting: incorporating advocacy groups and patient voices in clinical research, breakthrough research applications, and […]
Posted in Events, Global, Guest Blog, Meetings, R&D, Technology | Also tagged , , , , | Leave a comment

Abrams Talks Social Media at DIA

“It doesn’t turn me on to send a warning letter.” –Tom Abrams, during a Q&A at DIA.  Instead of repeating his yearly Drug Information Association (DIA) conference claim that social media guidance remains among the FDA’s Office of Prescription Drug Promotion’s (OPDP) “highest priorities,” to be published in due course, Tom Abrams, director of OPDP, […]
Posted in Advertising, E-Media, FDA, Legal, Marketing, Meetings, Patient Communication, Regulatory, social media, Strategy, Technology | Also tagged , , , , | Leave a comment

Europe: Expectations High for Rare Disease Day

Next week Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention. It is now an annual awareness-raising event co-ordinated by the European rare diseases lobby group, EURORDIS. For this year’s celebration, […]
Posted in Europe, Events, Global, Guest Blog, Orphan Drugs | Also tagged , , , | Leave a comment

Strange Bedfellows No More: EMA Moves Closer to Payers

That strict red line between regulatory authorization and market reimbursement is blurring pink – at least in Europe.  At a Drug Information Association [DIA] session earlier this week, European Medicines Agency [EMA] Senior Medical Officer Hans-Georg Eichler confirmed that the agency was finally moving to test the feasibility of a new, “holistic” approach to obtaining […]
Posted in Europe, FDA, Regulatory | Also tagged , , | Leave a comment
  • Categories

  • Meta